An evidence-based breakdown of which patients benefit most from Talkspace, including clinical data on text-based therapy, cost analysis, prescribing scope, and how the platform compares to alternatives.
An independent, evidence-based review of The Blue Zone's prescription and intake process for longevity-focused peptide and hormone therapies, including cost, legitimacy, and clinical context.
Independent clinical review of The Blue Zone longevity and peptide practice. Who benefits most, what the evidence supports, and how it compares to alternatives.
An independent comparison of Thirty Madison (Keeps, Cove, Picnic) and the top telehealth alternatives for hair loss, migraine, allergies, and sexual health.
Independent analysis of Thirty Madison's D2C telehealth portfolio including Keeps, Cove, and Picnic. We examine the clinical evidence behind their prescribed treatments, pricing, and how the company compares to alternatives.
An evidence-based analysis of Thirty Madison's telehealth brands (Keeps, Cove, Picnic, Honesty) and who benefits most from their D2C model for hair loss, migraine, allergy, and sexual health.
Thorne is a direct-to-consumer supplement company founded in 1984, now based in Charleston, SC, making 350+ products in two owned NSF-certified facilities.
An independent breakdown of Thorne's intake process, at-home testing, personalized supplement protocols, cost, and how the brand compares to alternatives.
Independent pricing analysis of Thorne supplements comparing cost per serving, third-party testing standards, and bioavailability data against mainstream and clinical-grade competitors.
Independent analysis of Thorne supplement quality, third-party testing results, real customer outcomes, and how Thorne products compare to alternatives based on published research.
An evidence-based breakdown of who benefits most from Thorne clinical-grade supplements, including specific patient profiles, cost analysis, and how Thorne compares to alternatives.
An independent breakdown of Thrive Cause's compounded peptide business model, pricing, legitimacy, and how it compares to alternatives in the telehealth peptide space.
An evidence-based comparison of Thrive Causemetics products against clinically tested alternatives for skincare, lashes, and complexion care, with dermatologist-backed options for every use case.
An evidence-based review of Thrive Causemetics' direct-to-consumer beauty model, ingredient transparency, charitable claims, and how the brand compares to clinical-grade alternatives.
Independent assessment of Thrive Causemetics' safety record, FDA compliance status, ingredient transparency, and regulatory positioning as a direct-to-consumer beauty-wellness brand.
A clinical breakdown of Transcend's hormone optimization intake process, what they prescribe, costs, legitimacy signals, and how the platform compares to alternatives.
Independent breakdown of Transcend hormone optimization costs, what you actually pay for membership, labs, medications, and how it compares to alternatives.
An independent comparison of TrimRx and its top alternatives for compounded GLP-1 therapy, telehealth weight loss, and peptide prescriptions in 2026.
An independent, evidence-based comparison of Twenty-Eight Health alternatives for birth control, emergency contraception, UTI treatment, and other reproductive health needs.
Viome uses RNA sequencing on stool and blood to recommend foods and supplements, priced $149-$599 plus $50-$90 monthly, but clinical validation remains limited.
An independent clinical assessment of Viome's microbiome testing and supplement platform, examining validation gaps, reproducibility concerns, and what the science actually supports.
An independent, evidence-based analysis of WeightWatchers' business model, clinical program efficacy, GLP-1 integration via Sequence acquisition, cost structure, and how it compares to telehealth alternatives.
Independent comparison of Willow's GLP-1 women's health telehealth model against alternatives ranked by cost, clinical oversight, insurance coverage, compounding, and hormone therapy integration.
Independent analysis of Willow, a cash-pay telehealth platform prescribing GLP-1 medications for women's weight management. Business model, legitimacy, cost structure, and clinical evidence reviewed.
An independent, evidence-based analysis of who benefits most from Willow's women-focused GLP-1 telehealth model, including candidacy criteria, cost considerations, and how it compares to alternatives.
Independent pricing breakdown of Winona's telehealth menopause and HRT platform, including consultation fees, medication costs, and how it compares to alternatives like Midi Health and Evernow.
Independent review of Wisp, the cash-pay telehealth platform for sexual health, UTIs, and BV. How it works, what it prescribes, pricing, and how it compares to alternatives.
Independent pricing breakdown of Wisp telehealth for UTI, BV, herpes, and birth control. Consultation fees, medication costs, and how Wisp compares to alternatives.
Is Wisp legit? A critical, evidence-based review of Wisp's safety record, regulatory compliance, prescribing practices, and how the telehealth sexual health platform compares to alternatives.
Independent pricing analysis of Women's International Pharmacy compounded BHRT. Real costs, hidden fees, and how WIP compares to alternatives for hormone therapy.
An independent clinical analysis of ZOE's personalized nutrition platform, CGM-based testing, and subscription model. Evidence-based review of efficacy, cost, and alternatives.
Independent pricing breakdown of ZOE's personalized nutrition program, including membership tiers, CGM sensor costs, gut microbiome test fees, and how ZOE compares to alternatives on cost and clinical evidence.
ZOE is an at-home CGM and gut microbiome test with app coaching, $354 plus $49-$69/month, best for prediabetic adults and diet non-responders.
A guide to bremelanotide (Vyleesi) safety in premenopausal women aged 30 to 49, covering adverse-event rates from the RECONNECT trials, blood-pressure warnings, nausea management, and long-term use considerations.
Evidence-based guide to bremelanotide (Vyleesi) use in adults 65 and older, covering dose adjustments, safety considerations, renal decline, and clinical monitoring for geriatric patients with HSDD.
The complete history of bremelanotide (Vyleesi), from its origins as a melanocortin analog to FDA approval for hypoactive sexual desire disorder in premenopausal women.
Kaiser Permanente coverage details for Vyleesi (bremelanotide), including formulary status, prior authorization requirements, step therapy, appeal options, and cost-saving alternatives for HSDD treatment.
A physician-level explanation of how bremelanotide (Vyleesi) activates melanocortin-4 receptors in the CNS to restore sexual desire in premenopausal women with HSDD.
Current regulatory status of bremelanotide (Vyleesi) across the United States, European Union, Canada, and United Kingdom, including approval history, mechanism of action, and clinical evidence from the RECONNECT trials.
Eliquis (apixaban) has a 12-hour half-life and clears in about 60 to 72 hours, roughly 2.5 to 3 days after your last dose. Kidney problems slow it down.
Evidence-based guide to antihypertensive medications that preserve exercise capacity, VO2max, and athletic performance while effectively lowering blood pressure.
A clinical breakdown of PCSK9 inhibitor costs, including evolocumab (Repatha), alirocumab (Praluent), and inclisiran (Leqvio). Covers list prices, net prices, insurance coverage, patient assistance programs, and how these drugs compare to generic statins.
A detailed breakdown of generic statin costs, PCSK9 inhibitor pricing, and inclisiran expenses. Compare atorvastatin, rosuvastatin, and simvastatin prices with and without insurance.
A clinical overview of GLP-1 receptor agonist therapy across key patient populations including type 2 diabetes, older adults, women, and pregnancy considerations.
Dana White's public health timeline, what the cited sources establish about TRT, and how testosterone treatment is assessed for an individual patient.
Mindy Kaling's published exercise statements, the limits of GLP-1 speculation, and how to separate a celebrity timeline from a prescription decision.
How to adjust tadalafil (Cialis) doses in patients with mild or moderate hepatic impairment, including FDA label limits, pharmacokinetic data, and clinical guidance for prescribers.
A physician-level breakdown of how tadalafil (Cialis) works, from nitric oxide release to PDE5 inhibition, smooth muscle relaxation, and the pharmacokinetic properties that set it apart from sildenafil and vardenafil.
Evidence-based guide to managing a missed dose of daily tadalafil (Cialis). Covers pharmacokinetics, clinical timing windows, and when to skip vs. double up.
Evidence-based monitoring schedule for Cialis (tadalafil) including baseline labs, follow-up exams, and ongoing safety checks for erectile dysfunction and BPH patients.
Evidence-based monitoring guide for tadalafil (Cialis) in adults aged 50 to 64, covering cardiovascular screening, renal and hepatic labs, blood pressure targets, drug interactions, and when to adjust dosing.
A complete timeline of Cialis (tadalafil) patents, Paragraph IV challenges, FDA generic approvals, and what the shift to generic competition means for pricing and access.
A clinician-grade review of tadalafil (Cialis) pharmacokinetics covering absorption, distribution, metabolism via CYP3A4, and the 17.5-hour elimination half-life that defines its 36-hour clinical window.
A clinician-grade review of tadalafil real-world evidence from registries, claims databases, and observational cohorts covering erectile dysfunction, BPH, cardiovascular safety, and adherence patterns.
A physician-level review of tadalafil's regulatory approvals, patent expirations, generic availability, and prescribing classifications across the US, EU, Canada, and the UK.
What is established, what is plausible but unproven, and what remains unresolved in the postmarketing safety record for tadalafil (Cialis), including FDA label actions and the drug's absolute nitrate contraindication.
Evidence-based monitoring guide for young adults aged 18-29 taking tadalafil (Cialis) for erectile dysfunction, covering labs, cardiovascular checks, fertility considerations, and follow-up intervals.
A clinical comparison of CJC-1295 (modified GRF 1-29) pricing, efficacy, and cost-effectiveness against sermorelin, ipamorelin, tesamorelin, and recombinant growth hormone.
Evidence-based guide to CJC-1295 (modified GRF 1-29) overdose recognition, expected adverse effects from excess dosing, half-life considerations for DAC vs. non-DAC variants, and step-by-step clinical management.
A clinical review of CJC-1295 (modified GRF 1-29) patent history, regulatory classification, compounding pharmacy access, and the realistic timeline for branded or generic approval.